Large prospective study of ramipril in patients with hypertension

Norman M Kaplan, L. E. Sproul, W. S. Mulcahy

Research output: Contribution to journalArticlepeer-review

28 Scopus citations


The results of controlled trials demonstrate that ramipril lowers blood pressure in hypertensive patients, has a long duration of action suitable for once-daily administration in most patients, and is well tolerated. To assess the efficacy and safety of ramipril in a large cross-section of patients, we conducted a multicenter, open-label, prospective study, in which 591 men or women with essential hypertension (diastolic blood pressure ≥ 95 and ≤ 114 mmHg) received ramipril on a regimen of 1.25 to 10 mg once daily for 8 weeks. Forty-one percent of the patients required 2.5 mg and 81% required ≤ 5 mg once daily at study completion. Compared with baseline, ramipril reduced mean systolic/diastolic blood pressure by 19.9/14.7 mmHg (P < 0.001/P < 0.001). Ramipril reduced diastolic blood pressure to ≤ 90 mmHg or by at least 10 mmHg in 84.1% of the patients. Response rates were similar regardless of age, gender, and race. No patient stopped ramipril because of an adverse event or experienced an unexpected adverse event. In our real-world study, low-dose ramipril given once daily controlled blood pressure in most patients and was well tolerated.

Original languageEnglish (US)
Pages (from-to)810-818
Number of pages9
JournalClinical Therapeutics
Issue number5
StatePublished - Nov 23 1993

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Large prospective study of ramipril in patients with hypertension'. Together they form a unique fingerprint.

Cite this